IDgenetix is a clinically validated
pharmacogenomic (PGx) test that incorporates drug-gene
interactions, drug-drug interactions and lifestyle factors to guide
medication management for patients’ neuropsychiatric conditions,
such as depression and anxiety
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced data from a single-site, open-label study demonstrating
the consistent impact of IDgenetix® on medication response and
remission rates in patients with major depressive disorder (MDD).
The study found that real-world patient outcomes were strongly
aligned to the results of a previously published randomized
controlled trial (RCT) that demonstrated IDgenetix-guided
medication management significantly improved response and remission
rates for patients with MDD.1,2 The data will be shared in a poster
at the 2023 Neuroscience Education Institute (NEI) Congress, taking
place Nov. 9-12, 2023, in Colorado Springs, Colorado.
“This study demonstrates the strong correlation between results
from a real-world analysis of IDgenetix and a published RCT from
Bradley and colleagues, which showed that patients whose medication
management was guided by IDgenetix were 2.65 times more likely to
achieve remission of depressive symptoms compared to patients whose
medication management was not guided by the test,” said Robert
Cook, Ph.D., senior vice president of research and development at
Castle Biosciences. “Results of the IDgenetix test allow doctors to
tailor medication selection for each patient, rather than relying
on trial and error, which may help patients achieve faster
remission from their depression symptoms.”
Poster #23: IDgenetix-Guided Medication Management for Major
Depressive Disorder: Confirmation of Randomized Controlled Trial
Outcomes by Real-World Evidence Presenting Author: Feng Cao,
Ph.D., Castle Biosciences Date & Time: Friday, Nov. 10, from
3-4:30 p.m. Mountain Time Location: Bartolin Hall
The study compared clinical outcome results from a multi-center
RCT (n=261) to real-world evidence (RWE) from a single-center,
non-randomized, open-label study (n=242).1,3 Response and remission
rates for patients with moderate to severe MDD were analyzed using
IDgenetix-guided medication management (guided) and compared to
patients receiving standard of care medication management
(unguided).
Patient response and remission rates strongly aligned between
both studies. Compared to patients in the unguided group, response
rates for the IDgenetix-guided participants improved by 37% in the
RCT vs. 32% in the RWE. Remission rates improved 49% in the RCT vs.
57% in the RWE.
The study also highlighted the impact of drug-drug interactions
(DDI) and lifestyle factors on the test results, indicating that
43% of the RCT recommendations and 24% of the RWE recommendations
were impacted by DDI and lifestyle factors, which are unique to
IDgenetix.
Overall, comparing the clinical outcome results from the RCT
with RWE demonstrated the consistent impact of IDgenetix on patient
response and remission rates. This study provides evidence-based
research that supports the clinical use of IDgenetix to guide
medication management in patients with MDD.
The poster can be viewed on Castle’s website here and will also
be available in the NEI Virtual Poster Library following the
presentation.
About IDgenetix®
IDgenetix® is an advanced pharmacogenomic (PGx) test designed to
guide medication selection and management for patients with
neuropsychiatric conditions, such as depression and anxiety.
IDgenetix provides important genetic information to clinicians to
help guide personalized treatment plans for their patients, with a
goal of helping patients achieve faster therapeutic response and
improving their chances of remission by identifying appropriate
medications more efficiently than the standard-of-care,
trial-and-error approach. IDgenetix integrates drug-gene, drug-drug
and lifestyle factor interactions in a clinically actionable report
and is supported by a published, peer-reviewed randomized
controlled trial that demonstrated clinical utility over the
standard of care when physicians reviewed IDgenetix results prior
to prescribing a medication. More information can be found at
www.IDgenetix.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the continued consistent impact
of IDgenetix on response and remission rates in patients with MDD;
and the potential of IDgenetix to help guide personalized treatment
plans for their patients, with a goal of helping patients achieve
faster therapeutic response and improving their chances of
remission by identifying appropriate medications more efficiently
than the standard-of-care, trial-and-error approach. The words
“can,” “may,” “potential,” “will” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation: subsequent study or trial results
and findings may contradict earlier study or trial results and
findings or may not support the results shown in this study,
including with respect to the discussion of IDgenetix in this press
release; actual application of our tests may not provide the
aforementioned benefits to patients; and the risks set forth under
the heading “Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2022, our Quarterly Report on Form 10-Q
for the three months ended September 30, 2023 and in our other
filings with the SEC. The forward-looking statements are applicable
only as of the date on which they are made, and we do not assume
any obligation to update any forward-looking statements, except as
may be required by law.
1. Bradley P, Shiekh M, Mehra V, et al. Improved Efficacy with
Targeted Pharmacogenetic-guided Treatment of Patients with
Depression and Anxiety: A Randomized Clinical Trial Demonstrating
Clinical Utility. J Psychiatr Res. 2018 Jan;96:100-107. doi:
10.1016/j.jpsychires.2017.09.024. Epub 2017 Sep 23. PMID:
28992526.
2. Cao F, Hanson A, Cook R, et al. The Importance of
Incorporating Drug-Drug Interactions and Lifestyle Factors in
Pharmacogenomics-Guided Medication Management for Patients with
Major Depressive Disorder in a Randomized Controlled Trial. Poster
at Psych Congress 2023: Sept 6-10, 2023; Nashville, Tennessee.
3. Cao F, Maciel A, Wosnik K, et al. Improved Response and
Remission Rates in Patients Receiving IDgenetix-guided Medication
Management for Major Depressive Disorder. Poster at 2023 American
Psychiatric Association (APA) Annual Meeting: May 20-24, 2023; San
Francisco, California.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108818488/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfica de Acción Histórica
De May 2023 a May 2024